Jebaraj et al. identified BRAF mutations present in about 2.8 percent of patients with CLL (4 out of 138 patients), whereas Jones et al. found that up to 14 percent (19/221 BRAF; 6/221 NRAS) of patients with CLL had either a BRAF or an NRAS mutation prior to the initiation of therapy or during relapse [11,12]. Here, NRAS is linked to B-cell chronic lymphocytic leukemia.